Novo Nodrisk stock dips on aggressive odder to buy Metsera, 'reckless' says Pfizer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pfizer earnings preview: Leerink trims estimates
November 3, 2025 4:00 PM ESTPfizer (NYSE: PFE) is set to report third-quarter results on Nov. 4, with analysts at Leerink Partners lowering earnings forecasts ahead of the release.
Leerink reduced its third-quarter earnings-per-share estimate by $0.10, or 13%, to $0.70, and full-year 2025 EPS by 3% to $3.04, within company guidance ($2.90$3.10).
The firm said it cut its 2025 Paxlovid... More
